To: LANCE B who wrote (7752)
From: 200mph Monday, Jul 3, 2000 9:20 AM ET
Reply # of 7754
ADVR should be getting a lot of attention in the coming weeks / months....I'm a buyer in the 40s
Applies to -- ADVR
Advanced Viral Research Corp. Cites Influence of 'Product R' On Opportunistic Infections
Advanced Viral Research Corp. Cites Influence of 'Product R' On
Opportunistic Infections
YONKERS, N.Y., Jun 29, 2000 (BW HealthWire) --
Dr. Shalom Z. Hirschman Discusses Recent Research on Human Papilloma
Virus and Dire Need for Effective Drugs in New Online Forum
In his second online forum on Advanced Viral Research Corp.'s (OTCBB:ADVR) Web
site -- adviral.com -- company President and CEO Dr. Shalom Z.
Hirschman discusses the dire need for more effective drugs to treat the
"opportunistic" infections that often develop in persons with AIDS.
Opportunistic infections are the most devastating complications in people with
AIDS. They occur as a result of the destruction of immune function by infection
with the human immunodeficiency virus (HIV). Human papilloma viruses (HPV) are
among the most common infections for which no therapy exists, or for which the
existing therapy is only marginally effective and fraught with severe toxic side
effects.
As Dr. Hirschman writes, "In persons whose immune systems have been compromised,
these infections become much more severe and can be life threatening. At
present, no effective drug has been approved (by the FDA) for the systemic
treatment of disseminated HPV infection."
However, recent research by scientists at the Advanced Viral Research Institute
has shown that Product R, an experimental drug being developed by the company as
a broad spectrum antiviral, interferes with the actual replication and growth of
HPV in cell culture. Earlier research by the company demonstrated that Product R
interferes with the expression of a key protein implicated in the development of
cervical cancer (the product of the E7 gene of HPV subtype 18).
Writes Dr. Hirschman, "These results indicate that Product R may be useful in
the treatment of disseminated human papilloma virus infection and in inhibiting
the development of cervical cancer. Indeed, these preliminary clinical results
suggest that Product R may be an effective non-toxic drug for both systemic and
topical therapy of disseminated HPV infection in people with AIDS."
To read the complete text of current and previous installments of "Dr.
Hirschman's Forum," visit adviral.com.
Shalom Z. Hirschman, M.D., joined Advanced Viral Research Corp. as president and
CEO following a 28-year affiliation with The Mt. Sinai School of Medicine and
The Mt. Sinai Hospital. During his tenure there, Dr. Hirschman held several
academic positions, including Director of the Division of Infectious Diseases,
Professor of Medicine, and Vice Chairman of the Department of Medicine. He spent
seven years at the National Institutes of Health in Bethesda, MD; he has been
published in many peer-reviewed journals, including THE NEW ENGLAND JOURNAL OF
MEDICINE, NATURE and SCIENCE, and founded one of New York City's first and most
active AIDS treatment and research centers.
About Advanced Viral Research Corp.
Advanced Viral Research Corp., based in Yonkers, New York, is a
biopharmaceutical firm committed to researching, developing and bringing to
market new, effective therapies for viral and other diseases, which will lead to
the alleviation of human suffering and diseases worldwide. Its flagship drug,
Product R, is a non-toxic immunomodulator that has been shown to have beneficial
therapeutic effects against viral diseases such as AIDS.
Note: This news release contains forward-looking statements that involve risks
associated with clinical development, regulatory approvals, including
application to the FDA, product commercialization and other risks described from
time to time in the SEC reports filed by ADVR. Product R is not approved by the
U.S. Food and Drug Administration or any comparable agencies of any other
countries.
CONTACT: Bratskeir & Company
Mike Rosen
212-679-2233
mrosen@bratskeir.com
URL: businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2000 Business Wire. All rights reserved.
Distributed via COMTEX.
-0-
KEYWORD: NEW YORK
INDUSTRY KEYWORD: MEDICAL
BIOTECHNOLOGY
PHARMACEUTICAL
Applies to -- ADVR -- DIPL
Advanced Viral Research Corp. to Present At 38th Annual Meeting of the Infectious Diseases Society of America
Advanced Viral Research Corp. to Present At 38th Annual Meeting of the
Infectious Diseases Society of America
YONKERS, N.Y., Jun 27, 2000 (BW HealthWire) --
Scientists to Discuss Antiviral Properties of Product R
Advanced Viral Research Corp. (OTCBB: ADVR) today announced that scientists from
the Advanced Viral Research Institute will give two presentations at the 38th
Annual Meeting of the Infectious Diseases Society of America (IDSA), taking
place September 7-10, 2000 in New Orleans, LA.
Led by Dr. Wenlin Huang, Advanced Viral Research Institute scientists will
discuss various aspects of the antiviral properties of Product R, a non-toxic
peptide nucleic acid (PNA) immunomodulator the company is developing as a
broad-spectrum antiviral drug. Details regarding the presentation will be
announced in late August or early September.
"We are honored to have an opportunity to present our most recent research
findings at such a prestigious forum," said Shalom Z. Hirschman, MD, president
and CEO of Advanced Viral Research Corp. "In addition, our colleagues in
Argentina have reported progress on our phase one clinical studies with Product
R. We continue to move with a determined focus toward our expectations of
beginning to file Investigational New Drug applications with the U.S. Food and
Drug Administration later this year. We are making strides in advancing our
mission to improve the quality of life of people suffering from a variety of
debilitating diseases."
Product R shows promise for the treatment of viral infections such as AIDS and
Human Papilloma Virus (HPV), and autoimmune diseases like rheumatoid arthritis.
Advanced Viral Research Corp. laboratory studies have shown that Product R
inhibits the production of both the CCR5 and CXCR4 chemokine receptors, the key
cellular co-receptors for the human immunodeficiency virus (HIV).
The Infectious Diseases Society of America represents more than 5,500
physicians, scientists and other health care professionals who specialize in
research and clinical aspects of infectious diseases. The Society's mission is
to promote and recognize excellence in patient care, education, research, public
health and the prevention of infectious diseases.
About Advanced Viral Research Corp.
Advanced Viral Research Corp., based in Yonkers, New York, is a
biopharmaceutical firm committed to researching, developing and bringing to
market new, effective therapies for viral and other diseases, which will lead to
the alleviation of human suffering and diseases worldwide. Its flagship drug,
Product R, is a non-toxic immunomodulator that has been shown to have beneficial
therapeutic effects against viral diseases such as AIDS.
Note: This news release contains forward-looking statements that involve risks
associated with clinical development, regulatory approvals, including
application to the FDA, product commercialization and other risks described from
time to time in the SEC reports filed by ADVR. Product R is not approved by the
U.S. Food and Drug Administration or any comparable agencies of any other
countries.
CONTACT: Bratskeir & Company
Mike Rosen, 212-679-2233
mrosen@bratskeir.com
URL: businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2000 Business Wire. All rights reserved.
Distributed via COMTEX.
-0-
KEYWORD: NEW YORK
INDUSTRY KEYWORD: BIOTECHNOLOGY
MEDICAL
PHARMACEUTICAL
PRODUCT |
